TickerTalks
Browse all tickers →
TickerTalks›$CORT
COCORT

Corcept Therapeutics Incorporated

$CORT·$8.9B·Biotechnology·Healthcare
——
Mentions · last 7 days
2026-06-07: 368 posts2026-06-08: 25 posts2026-06-09: 22 posts2026-06-10: 20 posts2026-06-11: 14 posts2026-06-12: 21 posts2026-06-13: 2 posts4740%
X counts updated 13h ago
COCORT
Corcept Therapeutics Incorporated$CORT
——474 posts0%
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CORT.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition and clinical binary events are the twin forces bifurcating biotech — ALT and VKTX carry high risk/reward ratios in the obesity race while IBRX's bladder/pancreatic immunotherapy catalysts define the oncology binary calendar. Gene editing (CRSP, BEAM, NTLA) is entering commercial maturation with Casgevy revenue scaling.

See how Biotechnology shapes $CORT

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $CORT's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+0.6%YTD
+32.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
180.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-1.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-1.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
11.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
98.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$-0.30$-0.14-111.3%
Q4 2025Feb 24, 2026$0.20$0.33-39.4%
Q3 2025Nov 4, 2025$0.16$0.18-11.1%
Q2 2025Jul 31, 2025$0.29$0.23+26.1%
Next earningsThu, Jul 30·consensus EPS $0.01

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$164.9M+4.9%98.3%-30.1%$-0.30$-17.0M
Q4 FY25$202.1M+11.1%98.7%2.2%$0.23$38.4M
Q3 FY25$207.6M+13.7%97.8%4.9%$0.19$54.5M
Q2 FY25$194.4M+18.7%98.2%13.7%$0.33$43.9M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$976.6M$951.6M – $990.0M$0.59$0.36 – $0.764
FY27$1.4B$1.2B – $1.8B$2.61$1.13 – $4.854
FY28$1.9B$1.8B – $2.0B$5.42$3.16 – $6.755
FY29$2.6B$2.2B – $3.2B$9.46$7.65 – $11.972
FY30$3.1B$2.7B – $3.8B$12.28$9.93 – $15.542

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+48.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 89.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $CORT is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 2William GuyerChief Development Officer20.0K sh$1.4MSellJun 1Sean MaduckSee Remarks25.0K sh$1.8MSellJun 1Atabak MokariCFO40.0K sh$2.8MSellJun 1Joseph K BelanoffCEO12.8K sh$895KSellMay 27Lyon Joseph DouglasSee Remarks5.0K sh$325KSellMay 27Sean MaduckSee Remarks75.0K sh$4.9MSellMay 5William GuyerChief Development Officer20.0K sh$1.0MSellMay 1Joseph K BelanoffCEO40.0K sh$2.0M
+ 26 other (12 awards · 6 exempts · 4 inkinds · 4 gifts) in window

See when $CORT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Corcept Therapeutics held its 2026 Annual Meeting on May 21, 2026. Shareholders elected 8 directors, ratified Ernst & Young LLP as independent auditor, approved advisory executive compensation, and approved an Amendment to the 2024 Incentive Award Plan adding 8,000,000 shares (effective May 21, 2026). The equity plan expansion represents modest incremental dilution to existing shareholders.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Corcept Therapeutics (CORT) issued a press release on April 30, 2026 announcing Q1 2026 financial results (quarter ended March 31, 2026) and a corporate update, furnished as Exhibit 99.1 and signed by CFO Atabak Mokari. The filing and press release are furnished under Exchange Act Regulation FD and are not filed for Section 18 liability purposes. No specific financial figures are disclosed in the filing body itself.

8-KPress release / Reg FDFeb 248-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 12 other (5 routine 8-Ks · 3 13Gs · 1 S-8 · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CORT Stock Rises 42% in a Month: Here's What You Should Knowzacks.com·6d agoCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®gurufocus.com·8d agoCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®businesswire.com·8d agoHealthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotechfool.com·9d agoState Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?fool.com·10d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$IBRX$ALT$RXRX$REPL
Voices on X · last 7 days

No standout posts about $CORT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport